Sartorius Stedim Biotech S.A.'s (EPA:DIM) top owners are public companies with 71% stake, while 17% is held by individual investors

Key Insights

• Sartorius Stedim Biotech's significant public companies ownership suggests that the key decisions are influenced by shareholders from the larger public
• Sartorius Aktiengesellschaft owns 71% of the company
• Institutional ownership in Sartorius Stedim Biotech is 12%

Every investor in Sartorius Stedim Biotech S.A. (EPA:DIM) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are public companies with 71% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

Meanwhile, individual investors make up 17% of the company’s shareholders.

Let's delve deeper into each type of owner of Sartorius Stedim Biotech, beginning with the chart below.

See our latest analysis for Sartorius Stedim Biotech

What Does The Institutional Ownership Tell Us About Sartorius Stedim Biotech?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in Sartorius Stedim Biotech. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Sartorius Stedim Biotech's historic earnings and revenue below, but keep in mind there's always more to the story.

Sartorius Stedim Biotech is not owned by hedge funds. The company's largest shareholder is Sartorius Aktiengesellschaft, with ownership of 71%. This implies that they have majority interest control of the future of the company. In comparison, the second and third largest shareholders hold about 1.3% and 1.2% of the stock.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of Sartorius Stedim Biotech

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our most recent data indicates that insiders own less than 1% of Sartorius Stedim Biotech S.A.. As it is a large company, we'd only expect insiders to own a small percentage of it. But it's worth noting that they own €6.4k worth of shares. It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling.

General Public Ownership

The general public-- including retail investors -- own 17% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Public Company Ownership

Public companies currently own 71% of Sartorius Stedim Biotech stock. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For instance, we've identified 2 warning signs for Sartorius Stedim Biotech that you should be aware of.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.